What doctors need to know about the Johnson & Johnson COVID-19 vaccine pause Pfizer, BioNTech amp up mRNA vaccine delivery targets amid Johnson & Johnson's delays White House won't buy more Pfizer, Moderna COVID-19 vaccine shots after J&J pause New approaches to AI, cell biology may have uncovered a novel drug target for COVID-19: Humans themselves Europe won't renew AstraZeneca, Johnson & Johnson COVID-19 vaccine contracts next year: report COVID-19 tracker: CDC panel reviews J&J vaccine data; Pfizer prices going up in Europe UPDATED Coronavirus tracker: Former CDC director advises controversial air purification company Moderna advancing early stage mRNA prospects to show depth beyond COVID-19 shot BioAge picks up muscle-aging program from Amgen, bringing pipeline count to 3 Featured Story | By Heather Landi While the rare blood clot cases associated with Johnson & Johnson's COVID-19 vaccine only involve six cases, pausing the vaccine's rollout is necessary out of an abundance of caution, Peter Marks with the FDA said. "We don’t have a lot of tolerance for friendly fire," he said. Here's what doctors need to know about signs or symptoms of a potential adverse reaction to the J&J vaccine. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy With Johnson & Johnson's COVID-19 vaccine under scrutiny in the U.S. and the company pausing shipments to Europe, Pfizer and BioNTech have stepped in to boost supply commitments on both sides of the Atlantic. read more By Robert King White House officials said they won't procure more doses of Moderna or Pfizer's COVID-19 vaccine in response to a pause of J&J's vaccine rollout while the FDA investigates rare blood clot cases. read more By Conor Hale By combining artificial intelligence and an extensive atlas of protein biology, Cyclica is taking new approaches to searching for old drugs that could fight COVID-19—and, now, it’s helped find what could become a first-in-class candidate. read more By Fraiser Kansteiner As Johnson & Johnson and AstraZeneca's COVID-19 vaccines grapple with safety concerns and delivery delays in Europe, the bloc has opted not to renew its supply contracts with companies next year, an Italian newspaper first reported. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky Johnson & Johnson's COVID-19 vaccine is under review at an independent vaccine committee of the CDC, which is reviewing data and will make recommendations about how to proceed. Plus, headlines from Pfizer and AstraZeneca. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Annalee Armstrong Moderna, armed with cash from the development of its COVID-19 vaccine, is advancing several other mRNA vaccine candidates in the clinic to show the biotech has more to offer than just the shot that made them world famous. read more By Amirah Al Idrus BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more quickly, decreasing muscle atrophy after a long hospital stay, or eventually, warding off frailty in older people. read more |
